Lacrat (Ticagrelor)

Ticagrelor is used in antiplatelet therapy to manage conditions associated with platelet‑driven thrombosis.

• Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke.
• Myocardial infarction: prevents recurrent ischemic events after an acute heart attack.
• Prevention of thrombotic cardiovascular events: lowers the incidence of clot‑related complications in high‑risk patients.

• Ticagrelor binds reversibly to the platelet P2Y12 ADP receptor, blocking ADP‑mediated activation of the G_i protein pathway. This inhibition prevents the conformational change of the glycoprotein IIb/IIIa receptor, reducing fibrinogen binding and subsequent platelet aggregation. By acting directly and without metabolic activation, ticagrelor provides rapid and consistent antiplatelet effects across a broad patient population. The effect is dose‑dependent and persists as long as the drug remains in circulation.

Ticagrelor may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dyspnea: shortness of breath, often occurring early in therapy.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Diarrhea: loose stools without severe dehydration.

Serious or Rare Side Effects

• Bleeding: including intracranial hemorrhage or gastrointestinal bleeding.
• Bradyarrhythmia: significant slowing of heart rate.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Severe allergic reaction: rash, angioedema, or anaphylaxis.

When prescribing ticagrelor, clinicians should consider several precautionary measures to ensure patient safety.

• Assess bleeding risk: evaluate history of hemorrhage, recent surgery, or anticoagulant use.
• Monitor renal function: dose adjustment may be needed in severe impairment.
• Review concomitant antiplatelet or anticoagulant therapy: avoid excessive anticoagulation.
• Caution in patients with a history of asthma or chronic obstructive pulmonary disease: dyspnea may be exacerbated.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Ticagrelor can interact with other medicines, altering its antiplatelet efficacy or increasing adverse event risk.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor plasma levels and bleeding risk.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy, increasing thrombotic risk.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin, direct oral anticoagulants): enhanced anticoagulant effect, monitor coagulation parameters.
• NSAIDs or aspirin: additive bleeding risk, assess gastrointestinal protection.
• Statins metabolized by CYP3A4 (e.g., simvastatin): may increase statin exposure, monitor for myopathy.
• P-glycoprotein inhibitors (e.g., verapamil): may modestly raise ticagrelor concentrations.